Immuno-oncology co-culture models market seen topping $1.8 billion by 2030

The immuno-oncology co-culture models market is forecast to grow from $0.93 billion in 2025 to $1.76 billion by 2030, driven by rising cancer research funding, demand for predictive preclinical testing and broader use of patient-derived and 3D model systems. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Immuno-oncology co-culture models give researchers a more realistic way to study how tumors and immune cells interact. - The systems are increasingly important for drug discovery, immunotherapy development and personalized cancer research. - The market’s growth reflects wider demand for precision medicine tools in oncology.

What happened: - The Business Research Company released its Immuno-Oncology Co-Culture Models Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the market will rise from $0.93 billion in 2025 to $1.06 billion in 2026. - The report projects the market will reach $1.76 billion by 2030. - The projected 2026-2030 CAGR is 13.6%. - North America held the leading market position in 2025. - Asia-Pacific is expected to grow faster than other regions over the coming years.

The details: - The report ties near-term growth to increased funding for cancer research. - The report cites wider use of in vitro disease models as a growth driver. - The report points to growing focus on immunotherapy development. - The report says demand is rising for predictive preclinical testing. - The report also highlights advances in cell culture technologies. - Longer-term growth is linked to personalized immuno-oncology investigations. - The report points to increasing adoption of patient-derived tumor models. - It also cites rising investment in next-generation preclinical platforms. - The report says organoid and microfluidic technologies are becoming more widely used. - Other trends include 3D tumor microenvironment models, patient-derived co-culture systems and predictive immunotherapy screening tools. - The report also flags deeper tumor-immune interaction studies as part of the shift toward more physiologically relevant cancer models. - The report describes immuno-oncology co-culture models as in vitro systems that combine immune cells and tumor cells to mimic the tumor-immune microenvironment. - These models let scientists observe cancer-immune interactions under controlled conditions. - The report says the systems improve assessment of immune responses, tumor behavior and immunotherapeutic effectiveness compared with traditional monoculture methods. - The report cites the global cancer burden as a major market driver. - In October 2025, Australian Government data showed about 169,759 new cancer diagnoses and roughly 53,545 cancer-related deaths. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The report also adds key technology coverage and future trend analysis. - Download a free sample of the market report - View the full market report

Between the lines: - The forecast suggests buyers are shifting toward models that better replicate human biology and produce more predictive data. - The emphasis on patient-derived systems, organoids and microfluidics points to a market moving away from simpler lab setups. - The region outlook suggests the biggest commercial upside may come from markets outside North America.

What's next: - The report’s forecast implies continued investment in preclinical platforms through 2030. - Broader use of 3D and patient-derived models is likely to shape product development and research workflows. - Faster regional growth in Asia-Pacific could shift where vendors target sales and partnerships.

The bottom line: - Immuno-oncology co-culture models are moving from a niche research tool to a core part of cancer drug development, and the market is on track for strong double-digit growth through 2030.